Replimune reaches agreement with US FDA to resubmit melanoma drug application
29/05/2026 13:03
Replimune reaches agreement with US FDA to resubmit melanoma drug application May 29 (Reuters) - Replimune REPL.O said on Friday it it has reached an agreement with the U.S. Food and Drug Administration to resubmit the marketing application for its experimental skin cancer drug after the regulator twice declined to approve the therapy.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly